Neurology and Neurosurgery

1-16 of 435

• 

  RestartResume

  Challenges and Opportunities in Migraine Management

  RestartResume

  Challenges and Opportunities in Migraine Management

  Global Neurology Academy

  Challenges and Opportunities in Migraine Management

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Yulia Orlova, MD

• 

  RestartResume

  Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results

  RestartResume

  Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results

  Project Oncology®

  Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results

  • 

    

    Alexandria May, PharmD, BCPS

  • 

    

    Nicholas Whipple, MD, MPH

• 

  RestartResume

  Endogenous Pathways in Migraine Care: Harnessing the Body's Natural Systems

  RestartResume

  Endogenous Pathways in Migraine Care: Harnessing the Body's Natural Systems

  Global Neurology Academy

  Endogenous Pathways in Migraine Care: Harnessing the Body's Natural Systems

  • 

    

    Ashley Baker, MSN, PMHNP

  • 

    

    Adriana Della Pietra, MD

• 

  RestartResume

  How Daily Light Habits Influence Migraine in Adolescents

  RestartResume

  How Daily Light Habits Influence Migraine in Adolescents

  Global Neurology Academy

  How Daily Light Habits Influence Migraine in Adolescents

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Carlyn Patterson Gentile, MD

• 

  RestartResume

  New Pathways in the Treatment of DMD

  RestartResume

  New Pathways in the Treatment of DMD

  CME/CE

  New Pathways in the Treatment of DMD

  1.00 credit

  • 

    

    Erika Finanger, MD, MS

  • 

    

    Aravindhan Veerapandiyan, MD

  1.00 credit

• 

  RestartResume

  Rethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms

  RestartResume

  Rethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms

  NeuroFrontiers

  Rethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Desiree Matthews, PMHNP-BC

• 

  RestartResume

  Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

  RestartResume

  Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

  NeuroFrontiers

  Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

  • 

    

    Ashvini Keshavan, MRCP, PhD

• 

  RestartResume

  Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions

  RestartResume

  Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions

  NeuroFrontiers

  Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions

  • 

    

    Shelina Ramnarine, PhD

  • 

    

    Michelle Scargle, MD

  • 

    

    Margaret Emerson, DNP, APRN, PMHNP-BC

• 

  RestartResume

  Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

  RestartResume

  Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

  Global Neurology Academy

  Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

  • 

    

    Brian P. McDonough, MD, FAAFP

  • 

    

    Ahmed Makhlouf, MD

• 

  RestartResume

  Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients

  RestartResume

  Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients

  NeuroFrontiers

  Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Ragy R. Girgis, MD, MS

  • 

    

    Desiree Matthews, PMHNP-BC

• 

  RestartResume

  Using fMRI to Identify Early Alzheimer’s Disease Subgroups

  RestartResume

  Using fMRI to Identify Early Alzheimer’s Disease Subgroups

  NeuroFrontiers

  Using fMRI to Identify Early Alzheimer’s Disease Subgroups

  • 

    

    Hamid Abuwarda, PhD, BS

• 

  RestartResume

  Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

  RestartResume

  Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

  NeuroFrontiers

  Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

  • 

    

    Sharon Sha, MD, MS

• 

  RestartResume

  Understanding Schizophrenia: The Role of Neurotransmission and Inflammation

  RestartResume

  Understanding Schizophrenia: The Role of Neurotransmission and Inflammation

  NeuroFrontiers

  Understanding Schizophrenia: The Role of Neurotransmission and Inflammation

  • 

    

    Jeffrey A. Lieberman, MD

• 

  RestartResume

  Harnessing AI to Predict and Prevent Schizophrenia Relapse

  RestartResume

  Harnessing AI to Predict and Prevent Schizophrenia Relapse

  NeuroFrontiers

  Harnessing AI to Predict and Prevent Schizophrenia Relapse

  • 

    

    Matcheri S. Keshavan, MD

• 

  RestartResume

  Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach

  RestartResume

  Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach

  NeuroFrontiers

  Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach

  • 

    

    Shelina Ramnarine, PhD

  • 

    

    Apurva Bhatt, MD

  • 

    

    Shannon Pagdon, BA

• 

  RestartResume

  Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access

  RestartResume

  Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access

  NeuroFrontiers

  Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    David Kimhy, PhD

• Prev
• 1
• 2
• 3
• …
• 27
• 28
• Next